HIF1A and pulmonary fibrosis: A significant decrease in HIF-1α levels was detected during the trial after treatment with Vasa in Group A. Our earlier preclinical study on AV by Gheware et al. showed that in mouse models of hypoxia-hemostasis, pulmonary fibrosis, and sepsis, in addition to other parameters, HIF-1α levels were reduced with oral treatment of AV [18].